Navigation Links
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
Date:2/14/2008

CHESHIRE, Conn., Feb. 14 /PRNewswire-FirstCall/ -- The Oklahoma Medical Research Foundation ("OMRF") and Alexion Pharmaceuticals, Inc. ("Alexion," Nasdaq: ALXN) today announced that Alexion has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology.

Background

The patents cover inventions made by OMRF in the 1980s relating to the treatment of complement system mediated disorders, to which Alexion has had limited rights as a licensee since the inception of the company. In the 1990s, Alexion began programs to create and develop monoclonal antibodies capable of blocking the body's complement system. One result of these Alexion programs was the development of Soliris(R), which was approved for marketing by the U.S. Food and Drug Administration and by the European Commission during 2007. Soliris(R) (eculizumab) is a complement inhibitor product developed and marketed by Alexion for the treatment of paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease.

"Soliris opened a major new therapeutic avenue for patients with PNH, and the scientists at Alexion had to overcome tremendous obstacles to make this treatment a reality," said OMRF President Stephen Prescott, M.D. "I am proud that Peter Sims, M.D., Ph.D., and Therese Wiedmer, Ph.D., while working as scientists at OMRF and in their subsequent careers, had the opportunity to contribute to bringing this much-needed treatment to patients suffering from a life-threatening disease."

"Complex scientific breakthroughs are often built by combining research advances from different sources," said David Keiser, President and Chief Operating Officer of Alexion. "OMRF is widely respected for its technological accomplishments, and we thank the OMRF team for its contributions to the development of our anti-complement technology."

Under an agreement recently executed by the two organizations, Alexion will pay O
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
2. Alexion to Present at Bear Stearns Healthcare Conference
3. Linc Facility Services Acquires Morse Medical
4. Acrongenomics Acquires Equity Stake in Molecular Vision
5. Inverness Medical Innovations Acquires ParadigmHealth
6. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
7. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
10. Neogen Acquires Assets of Rivard Instruments
11. Advanced Instruments Acquires Mart Microbiology B.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Telomere Biosciences, LLC (Telomere Biosciences) ... for Dogs" with Telomerase Activation Complex , ... world for dogs. Telomeres are the protective caps ... body. A wealth of ground-breaking research by some ... and Aging, including Nobel laureates, has demonstrated a ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
Breaking Biology Technology:Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... 19, 2011 Tissue Genesis, Inc., an emerging leader ... that it has begun clinical trials for peripheral vascular ... vascular grafts at the University of Louisville Hospital.  Tissue ... using the patient,s own adipose-derived adult stem cells (ASCs) ...
... Ohio New research suggests that currently available types of ... skin in laboratory tests, and may be on their way ... Researchers compared the response of synthetic skins to rat skin ... treatment, and the results indicated they both reacted similarly. ...
... 2011 Accelovance, a privately held clinical research ... Organization (CRO)" for a third consecutive year. The ... Gaylord National Hotel and Convention Center, Washington, D.C., ... to honor and generate recognition of the efforts, ...
Cached Biology Technology:Tissue Genesis Begins FDA-Approved Clinical Trial 2Tissue Genesis Begins FDA-Approved Clinical Trial 3For testing skin cream, synthetic skin may be as good as the real thing 2For testing skin cream, synthetic skin may be as good as the real thing 3Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO" 2
(Date:8/21/2014)... SHELTON, Conn. , Aug. 21, 2014 ... on the growing mobile commerce market, announced today that ... purchase common stock to be issued in its proposed ... been approved for listing on The Nasdaq Capital Market, ... of the common stock and warrants, and will trade ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... available in German . ... have jaws have four fins or limbs, one pair in front ... of evolution, into a marvelous variety of fins, legs, arms, flippers, and ... arrangement of two pairs of appendages? Because we have a belly. ...
... Yale School of Medicine researchers provides insight into how much ... reproductive health. Published in the Jan. 27 issue of ... of reproductive-age women had never discussed their reproductive health with ... provider less than once a year or never. ...
... embryonic stem cells of high clinical quality. It also allows ... The discovery is a big step forward for stem cell ... and thereby curing serious illnesses such as diabetes and Parkinson,s ... from surplus in vitro fertilized (IVF) embryos that are not ...
Cached Biology News:How did we get 4 limbs? Because we have a belly 2How did we get 4 limbs? Because we have a belly 3The science of baby-making still a mystery for many women 2New method increases supply of embryonic stem cells 2
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: